PDF herunterladen
CC BY-NC-ND 4.0 · Ibnosina Journal of Medicine and Biomedical Sciences 2019; 11(01): 35-37
DOI: 10.4103/ijmbs.ijmbs_92_18
Case Report

Sodium-glucose co-transporter 2 inhibitor-induced euglycemic diabetic ketoacidosis in a Type 2 diabetes patient not absolutely insulin-deficient!

Mamoun Mukthar
1   Department of Diabetes and Endocrinology, Rashid Center for Diabetes and Research, Ajman
,
Sijomol Skaria
1   Department of Diabetes and Endocrinology, Rashid Center for Diabetes and Research, Ajman
,
Ramadan Beshir Ahmed
2   Department of Internal Medicine, Sheikh Khalifa General Hospital, Ajman
,
Akrem Elmalti
1   Department of Diabetes and Endocrinology, Rashid Center for Diabetes and Research, Ajman
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Sodium-glucose co-transporter 2 (SGLT2) inhibitors are the newest class of oral antidiabetic agents. In addition to glucose lowering, they have other advantageous effects on blood pressure and body weight. The use of those agents has increased exponentially after the emerging evidence of cardiovascular protection following the publication of the EMPA-REG OUTCOME study. Although they are relatively safe and effective, they are not without side effects. Perhaps, the most serious complication is euglycemic diabetic ketoacidosis (DKA). Several cases were reported in the literature. We describe a case of severe DKA in association with the use of an SGLT2 inhibitor (empagliflozin) in a 69-year-old male with type 2 diabetes who is not absolutely insulin deficient following knee replacement. The case highlights the increased risk of DKA and the importance of discontinuation of SGLT2 inhibitors before major surgery.

Key-words:

Euglycemic diabetic ketoacidosis - insulin deficiency - sodium-glucose cotransporter-2 inhibitors - type 2 diabetes

Financial support and sponsorship

Nil.




Publikationsverlauf

Eingereicht: 20. Dezember 2018

Angenommen: 01. Januar 2019

Artikel online veröffentlicht:
07. Juli 2022

© 2019. The Libyan Authority of Scientific Research and Technologyand the Libyan Biotechnology Research Center. All rights reserved. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License,permitting copying and reproductionso long as the original work is given appropriate credit. Contents may not be used for commercial purposes, oradapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Devineni D, Curtin CR, Polidori D, Gutierrez MJ, Murphy J, Rusch S, et al. Pharmacokinetics and pharmacodynamics of canagliflozin, a sodium glucose co-transporter 2 inhibitor, in subjects with type 2 diabetes mellitus. J Clin Pharmacol 2013;53:601-10.
  • 2 Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28.
  • 3 FDA Safety Communication. FDA Warns that SGLT2 Inhibitors for Diabetes may Result in a Serious Condition of too Much Acid in the Blood. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm446845.htm. [Last accessed on 2018 Feb 02].
  • 4 Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015;100:2849-52.
  • 5 Kibbey RG. SGLT-2 inhibition and glucagon: Cause for alarm? Trends Endocrinol Metab 2015;26:337-8.
  • 6 Hayami T, Kato Y, Kamiya H, Kondo M, Naito E, Sugiura Y, et al. Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig 2015;6:587-90.
  • 7 Peters AL, Buschur EO, Buse JB, Cohan P, Diner JC, Hirsch IB, et al. Euglycemic diabetic ketoacidosis: A potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1687-93.
  • 8 Kalra S, Sahay R, Gupta Y. Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis. Indian J Endocrinol Metab 2015;19:524-8.